Get the Stockscreener App
1.84
0.54%
-0.01
After Hours:
1.86
0.02
+1.09%
Neumora Therapeutics Inc stock is traded at $1.84, with a volume of 1.29M.
It is down -0.54% in the last 24 hours and down -18.22% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.85
Open:
$1.91
24h Volume:
1.29M
Relative Volume:
1.07
Market Cap:
$340.92M
Revenue:
-
Net Income/Loss:
$-222.39M
P/E Ratio:
-1.3868
EPS:
-1.3268
Net Cash Flow:
$-193.40M
1W Performance:
+10.18%
1M Performance:
-18.22%
6M Performance:
-19.65%
1Y Performance:
+170.71%
1-Day Range:
$1.80
$1.93
1-Week Range:
$1.66
$1.98
52-Week Range:
$0.6607
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.84 | 342.78M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-12-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-27-25 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-16-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora Therapeutics (NMRA): Stock Holds Steady at $1.85 as Key Support and Resistance Levels TightenGap Down Bounce Plays - Newser
Neumora Therapeutics (NMRA) Holds Steady at $1.85 as Stock Navigates Tight RangeTrader Community Signals - Newser
Neumora’s NMRA-323511 Alzheimer’s Agitation Study Reaches Completion, Setting Up the Next Investor Catalyst - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
Neumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Ami Fadia Reiterates Buy on Neumora, Sees Compelling Risk-Reward Ahead of Phase 3 Readouts with Unchanged $8 Price Target - TipRanks
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Inside INdiana Business - FinancialContent
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TradingKey - TradingKey
William Blair Maintains Neumora Therapeutics(NMRA.US) With Buy Rating - Moomoo
Neumora (NASDAQ: NMRA) ends Q1 2026 with $147M cash and key Phase 3 data ahead - Stock Titan
Neumora Therapeutics Q1 2026 Earnings Report - MarketBeat
Neumora (NASDAQ: NMRA) trims Q1 2026 loss and funds runway into Q3 2027 - Stock Titan
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Depression drug data due this quarter as Neumora cash lasts to 2027 - Stock Titan
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Why Neumora Therapeutics (NMRA) might be the steady performer you need (Technical Strength) 2026-05-06VWAP Deviation - Newser
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in - BioSpace
Invus and Avicenna holdings disclosed in Neumora Therapeutics (NASDAQ: NMRA) filing - Stock Titan
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Neumora Therapeutics (NMRA) price target increased by 19.25% to 9.33 - MSN
Stifel Maintains Neumora Therapeutics (NMRA) Hold Recommendation - MSN
Mizuho Securities Remains a Buy on Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pr - Benzinga
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
NMRA Technical Analysis | Trend, Signals & Chart Patterns | NEUMORA THERAPEUTICS INC (NASDAQ:NMRA) - ChartMill
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Neumora Therapeutics (NASDAQ: NMRA) sets 2026 proxy votes on board, auditor and executive pay - Stock Titan
Neumora Therapeutics (NMRA) is among the best penny stocks set to explode - MSN
Neumora Therapeutics (NMRA) Stock Turns Bearish on Neumora Therapeutics (NMRA) (+1.48%) 2026-04-15Risk Management - Cổng thông tin điện tử tỉnh Lào Cai
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE) - The Globe and Mail
NMRA Q4 2025 Earnings: Neumora Therapeutics misses EPS estimates, reports no revenuePopular Market Picks - Xã Thanh Hà
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode - Insider Monkey
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Rally Mode: Is Neumora Therapeutics Inc forming a breakout patternInflation Watch & Growth Oriented Trade Recommendations - baoquankhu1.vn
Short Squeeze: Does Neumora Therapeutics Inc stock have upside surprise potentialEarnings Summary Report & Community Consensus Stock Picks - baoquankhu1.vn
H.C. Wainwright Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Is Neumora Therapeutics (NMRA) Stock Good for Long Term | Price at $2.12, Up 6.00%Community Buy Signals - Cổng thông tin điện tử tỉnh Lào Cai
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neumora Therapeutics Inc Stock (NMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):